Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass.
about
Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysisRecombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patientsr.hu-erythropoietin (EPO) treatment of pre-ESRD patients slows the rate of progression of renal declineCyclooxygenase inhibition with acetylsalicylic acid unmasks a role for prostacyclin in erythropoietin-induced hypertension in uremic ratsRecombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients.Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients.Myoblast transfer of human erythropoietin gene in a mouse model of renal failureThe anaemia of silent diabetic nephropathy-prevalence, physiopathology, and management.Meta-analysis of diabetic nephropathy associated genetic variants in inflammation and angiogenesis involved in different biochemical pathways.Erythropoietin therapy in patients with chronic renal failurePrevention of 11-deoxycorticosterone-salt-induced glomerular hypertrophy and glomerulosclerosis by dietary phosphate binderImportance of anemia in the chronic Cardiorenal syndrome: effects on renal function after heart transplantationMechanisms of disease: erythropoietin--an old hormone with a new mission?Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications.A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats.Anemia, diabetes, and chronic kidney disease.Restricted Use of Erythropoiesis-Stimulating Agent is Safe and Associated with Deferred Dialysis Initiation in Stage 5 Chronic Kidney Disease.Animal models of cardiorenal syndrome: a review.Genetics of diabetic nephropathy: a long road of discovery.The association between low blood lead levels and the prevalence of prehypertension among nonhypertensive adults in Korea.A nonerythropoietic derivative of erythropoietin inhibits tubulointerstitial fibrosis in remnant kidney.Renal protective effects of erythropoietin on ischemic reperfusion injury.Role of oxidative stress in erythropoietin-induced hypertension in uremic rats.Haematocrit and the risk of developing end-stage renal disease.Mechanisms and mediators of hypertension induced by erythropoietin and related molecules.Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose.Abnormal rheology in cyanotic congenital heart disease--a factor in non-immune nephropathy.Beneficial effects of erythropoietin on haematological parameters, aerobic capacity, and body fluid composition in patients on haemodialysis
P2860
Q24186430-95A9BD23-1B73-4EF1-95DD-2DD99EF773B3Q24246372-B5E69C16-F8B7-47A3-BF09-7A9101017C6BQ24806325-BE7B616B-FAC8-40F4-BF6C-8AFEC0E846AFQ28185576-00E60960-164B-490D-98B2-A865A9EB33E5Q31027980-280FC57A-8C08-48A0-B393-B1E39195E6F9Q31832576-8BED5E94-B18A-448C-AC05-0F917607A59CQ34210746-30BCC587-8952-4ECA-BAEE-DF05C9B37164Q35208122-02BF7B82-9323-4E9C-85A1-CEEF85C23805Q35299817-81200DE2-BD0A-4D1E-90A2-162225875174Q35533180-94A87268-46C4-4FDD-8380-68CCF5DB1863Q35811445-47F92D2D-5A25-4B93-9F29-E0FA4B4019DCQ36576777-501B0228-CCB7-4F10-9081-58EFD70F56E6Q36600985-F8DF6986-CF9F-46E4-B083-6520AF36224BQ36657594-1E3345D0-029A-47EE-8181-8FCF5D300025Q37000231-BEB72B4C-7077-4F11-B718-914E7FADFAB7Q37235968-555F7499-BEDD-4594-8208-76DBCCA81B1FQ37685792-83EF8466-E753-41CF-9023-626FF3C209D7Q37930478-2F504477-AA5E-4A20-9806-6CF2A8E1B3F2Q38478054-6DEAA580-03D7-4F9C-8D1F-67E82DE997DDQ39816738-685458EB-4855-4DCA-9B3E-0F0EFC1A014DQ42277386-BB720CC3-ABB8-4389-B518-2320D9320ABEQ43043902-55FFCA4B-973D-452C-9831-8F493B92F3BDQ43216561-7FE7B1AD-4B3F-492E-9EFE-34DACC6D6C15Q44397975-FCD842A0-DF50-4EA8-8790-EACA00825CC5Q47307152-EAD78512-8B35-43F4-BE74-753B3609BF14Q51546144-454D4381-A930-473E-B055-ACE06555AB34Q52959931-37316A50-C09C-47FA-ABB7-25DF0A545C81Q57673660-AF20FB0A-39EC-42B4-9F24-BCE77F69C810
P2860
Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass.
description
1988 nî lūn-bûn
@nan
1988 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1988 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1988年の論文
@ja
1988年論文
@yue
1988年論文
@zh-hant
1988年論文
@zh-hk
1988年論文
@zh-mo
1988年論文
@zh-tw
1988年论文
@wuu
name
Anemia lessens and its prevent ...... rats with reduced renal mass.
@ast
Anemia lessens and its prevent ...... rats with reduced renal mass.
@en
type
label
Anemia lessens and its prevent ...... rats with reduced renal mass.
@ast
Anemia lessens and its prevent ...... rats with reduced renal mass.
@en
prefLabel
Anemia lessens and its prevent ...... rats with reduced renal mass.
@ast
Anemia lessens and its prevent ...... rats with reduced renal mass.
@en
P2093
P2860
P356
P1476
Anemia lessens and its prevent ...... rats with reduced renal mass.
@en
P2093
B M Brenner
D L Garcia
H G Rennke
S Anderson
P2860
P304
P356
10.1073/PNAS.85.16.6142
P407
P577
1988-08-01T00:00:00Z